Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 6/20 | 0.49 |
| ▸ | NOS3 | P29474 | 5/20 | 0.49 |
| ▸ | NOS1 | P29475 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | LSS | P48449 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13887902 | 0.85 | KDM4E (0.58) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL8251941 | 0.85 | HTR2A (0.58) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL9451684 | 0.84 | KDM4E (0.49) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL18412166 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL17285892 | 0.84 | LSS (0.64) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL17286021 | 0.84 | NOS2 (0.59) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL8442356 | 0.83 | KDM4E (0.68) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL3085764 | 0.81 | HRH3 (0.74) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL17286016 | 0.81 | HTR2A (0.55) | KDM4EALDH1A1LTA4HHRH3HRH4 | |
| SCHEMBL29956663 | 0.80 | KDM4E (0.53) | KDM4EALDH1A1LTA4HHRH3HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313732-B1 | OXINDOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-11-03 | — | — | EP | disclosed |
| US-6720332-B2 | Oxindole derivatives | SMITHKLINE BEECHAM CORPORATION | 2004-04-13 | — | — | US | disclosed |
| US-20030195189-A1 | Oxindole derivatives | SMITHKLINE BEECHAM CORPORATION | 2003-10-16 | — | — | US | disclosed |
| EP-1313732-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002020524-A1 | OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195189-A1 | Oxindole derivatives | CDK4, CCNI, CCNO | KDM4E 1346/4885ALDH1A1 2383/4885LTA4H 3392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.